Articles On Actinogen Medical (ASX:ACW)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

A global study links Alzheimer’s disease with kidney malfunction FDA czar Dr Marty Makary outlines the agency’s priorities Pro Medicus fesses up to a cyber breach   The quest for an Alzheimer’s disease cure has taken a new twist, with an...

The ASX 200 fell 2.66% in November, with the tech sector dumping almost 12% Concerns about an AI-fuelled market bubble weighed on global sentiment as Aussie inflation came in hotter-than-expected Mount Ridley Mines continued its stellar ru...

Highlights Broad uptrend momentum seen across diverse sectors. Multiple companies experience renewed chart strength. Downtrend signals highlight shifting market sentiment. A comprehensive exploration of rising and weak...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

If you’ve been a consistent reader of Fat Tail Daily or our paid subscription services, you’ve likely done well from the recent critical minerals and rare earth rally. It’s been one of the few themes all Fat Tail Editors have firmly agreed...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Phase 2b/3 Alzheimer’s trial enrolment passes 50% – twenty US trial sites continu...

Neuren’s US partner Acadia reports a 14% sales boost Look out for a slew of advanced clinical trial results in early 2026 IDT Australia shares plunge up to 39% after CEO departs “with immediate effect”   Despite firming US sales of its Re...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Eye drug developer Opthea’s cash balance has more than halved as the company wraps up its failed trials Poynovo shares gain 10% after a cracker full-year result Microx leads today’s sector gains after a US deal with a mystery party    The...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studyi...

Neurizon Therapeutics (ASX:NUZ) has this week arrived at its next “watershed moment” as it looks to become a leader in neurodegenerative disease treatments, executing a global license agreement with Elanco Animal Health Inc. Listen to th...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Marmota Limited (ASX:MEU) will be starting its first-ever drilling at Greenewood within the next week, with the maiden run – which will double the holes at the project – coming just days after the explorer confirmed the title transfer. L...

In this HotCopper Capital Compass interview, Race Oncology (ASX:RAC) chairman Dr Pete Smith discusses the company’s “safe and successful” Phase One clinical trials and the RC220 plus doxorubicin dosing done at the time. Listen to the Hot...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Interim analysis planned for January 2026 with final trial results in late 2026 H...

Actinogen Medical (ASX:ACW) has this week enrolled its 100th participant for its “pivotal” XanaMIA phase 2b/three trial for Xanamem, its investigational drug designed to treat the cognitive decline in Alzheimer’s disease. Listen to the H...

Highlights BVF Partners exits Syntara citing fund size constraints, not program performance Trial data for myelofibrosis drug candidate shows continued progress Syntara to discuss future clinical development path with US FDA...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Nova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the back of a flagged US pharmaceutical tariff Flu vaccines don’t give you autism, but do they work? Recce is raising up to $15.8 million to fund...

Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday Blame factor 1: Trump and his 25% US auto import tariffs, set to come into play early April Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too   ...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

There are several ASX biotech companies developing drugs to treat complex neurological conditions Global neurological disorder drugs market size set to reach US$149.17 billion by 2032 Petra Capital’s Tanushree Jain says neurological disord...

Profit-making ASX biotechs have been caught up in the market rout During Brain Health Week, let’s not forget about dementia risks Argent looks for Malta site deal While few stocks or sectors have escaped the market correction – or almost...

The search for an effective treatment for neurological conditions like Alzheimer’s disease remains one of the most urgent challenges in global healthcare. In 2025, Australian biotech company Actinogen Medical Ltd (ASX:ACW) is making signifi...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

ASX drops as Trump tariffs fuel market jitters Canada and China hit back with tariffs of their own Suncorp, Insignia and HCW down after bad news   The ASX had a bad Tuesday after Donald Trump confirmed he was going ahead with those tariff...

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese partner   Some healthcare analysts be...

Finding a successful treatment for neurological conditions such as Alzheimer’s Disease is a pressing need both in Australia and globally. Thankfully, there’s a company taking steps to tackle the issue head-on through its development of a...

Actinogen Medical Ltd (ASX:ACW) said its net loss after tax for the six months to December 2024 decreased by 29% to $8,168,979 – compared to $11,556,659 in the HY24 – largely based on the ramping up of development activity for lead molecule...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Late-stage Alzheimer’s trial opens 10 new sites in USA, with results due in 2025...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Late-stage trial in Alzheimer’s opens 10 sites in US, with results due in 2025 a...

The ASX200 closed down 0.03% at 8,423 points. Gold rose after China’s central bank added bullion to its reserves in November, resuming a key pillar of support for the precious metal. Bullion climbed by 0.5% to US$2,640. Energy was the...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

For years, people dreamed that science would one day create a pill to cure all ills.  Today, one small pill may not cure everything, but it holds the potential to transform cognitive medicine by addressing debilitating conditions like de...

Amid improving sector sentiment, Actinogen says its Alzheimer’s trial is off to a flier Telix shares start trading on the Nasdaq tonight More of the Trump-edelic effect? Tryptamine shares are on a roll   Actinogen Medical (ASX:ACW) report...

Actinogen Medical Ltd (ASX:ACW) has received a $9 million R&D (research and development) tax incentive rebate for the 2024 fiscal year, based on clinical tests of its lead compound Xanamem – a prospective therapy for Alzheimer’s Disease...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Emvision expects to release trial results for its Emu stroke-detection device in November Syntara’s rare blood cancer program gathers pace Actinogen says 25 patients have been treated in its 200-candidate Alzheimer’s disease study   Quart...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Research reports on ASX-listed companies, to download in full. **** -Actinogen Medic...

Cancer drug developer Chimeric Therapeutics eyes minimum $5 million raising ‘The next Telix’, Clarity gets FDA go-ahead for prostate cancer trial LTR Pharma fleshes out erectile dysfunction trial results   Cancer cell therapy house Chimer...

If you have retirement on the horizon, then now could be the time to start thinking about building an investment portfolio that is appropriate for this stage of your life. But what sort of ASX shares would be suitable for someone that is re...

S&P/ASX 200 Index (ASX: XJO) tech stock NextDC Ltd (ASX: NXT) has had a great run over the past year. On Thursday, shares in the data centre operator and developer closed 2.44% higher, trading for $17.64 apiece. That sees the Next...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Renewed optimism lifted the S&P/ASX 200 by 3% in September, closing at a record 8,239.20 points S&P Dow Jones Indices said small cap companies outperformed in September, with the materials sector rebounding 13%  Mithril Silver and...